Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046

prnasiaOctober 18, 2021

Tag: Bispecific Antibody , KN046 , Alphamab Oncology

PharmaSources Customer Service